Lysophosphatidic acid as the initiator of neuropathic pain.
Division of Molecular Pharmacology and Neuroscience, Graduate School of Biomedical Sciences, Nagasaki University, Japan.
Journal Article: Biological & Pharmaceutical Bulletin (impact factor: 1.81). 01/2011; 34(8):1154-8.
Abstract
Source: PubMed
Comments on this publication
ResearchGate members can add comments. Sign up now and post your comment!
Similar publications
Lipoprotein-derived lysophosphatidic acid promotes atherosclerosis by releasing CXCL1 from the endothelium.
Cell metabolism. 13(5):592-600.
EGF and angiotensin II modulate lysophosphatidic acid LPA(1) receptor function and phosphorylation state.
Biochimica et biophysica acta. 1810(12):1170-7.
NHERF2 specifically interacts with LPA2 receptor and defines the specificity and efficiency of receptor-mediated phospholipase C-beta3 activation.
Molecular and cellular biology. 24(11):5069-79.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

